Highlights Acticor Biotech SAS

Equities

ALACT

FR0014005OJ5

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
1.14 ^EUR	+35.71%		+35.71%	-60.69%

May. 15	Acticor: 'new perspectives' in stroke treatment	CF
May. 15	Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acticor: 'new perspectives' in stroke treatment	May. 15	CF
Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024	May. 15	CI
Acticor Biotech: rebound from the previous day's tumble	Apr. 26	CF
Acticor Biotech: Phase 2/3 study fails	Apr. 25	CF
Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment	Apr. 25	CI
Acticor Biotech: phase 2/3 results expected in May	Apr. 16	CF
Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024	Apr. 15	CI
Acticor Biotech: falls after capital increase	Mar. 15	CF
The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack	Feb. 07	CI
Acticor: 'we are delighted to observe the market's reaction'.	Jan. 29	CF
Acticor Biotech continues to soar, hopes for stroke treatment	Jan. 24	CF
Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal	Jan. 23	CI
Acticor: capital increase at a significant discount	Nov. 28	CF
Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	Nov. 07	MT
ACTICOR BIOTECH Announces Timely Completed Patient Recruitment of Its Phase 2/3 Study in Stroke	Nov. 07	CI
Acticor Biotech SAS Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-26	CI
Acticor Biotech and University of Birmingham Announces The UK Regulatory Agency Approves the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks	23-09-07	CI
Acticor Biotech Announces Results of Its Collaboration with Brainomix Limited	23-08-31	CI
Acticor Biotech Announces Progress in Discussions with EU and US Regulatory Agencies	23-05-30	CI
Acticor Biotech SAS Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Acticor Biotech SAS

Equities

ALACT

FR0014005OJ5

Highlights

Filters